[go: up one dir, main page]

UY26454A1 - 4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL - Google Patents

4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL

Info

Publication number
UY26454A1
UY26454A1 UY26454A UY26454A UY26454A1 UY 26454 A1 UY26454 A1 UY 26454A1 UY 26454 A UY26454 A UY 26454A UY 26454 A UY26454 A UY 26454A UY 26454 A1 UY26454 A1 UY 26454A1
Authority
UY
Uruguay
Prior art keywords
tetrahydrokinoline
carboxamine
substituted crystal
crystals
substituted
Prior art date
Application number
UY26454A
Other languages
Spanish (es)
Inventor
Lyle Robinson Brostrom
Douglas John Meldrum Allen
Troy Anthony Appleton
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26454A1 publication Critical patent/UY26454A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen formas cristalinas de un inhibidor de CETP, procedimientos para preparar los cristales, procedimientos de uso de los cristales y composiciones farmacéuticas que contienen los cristales.Crystalline forms of a CETP inhibitor, methods of preparing the crystals, methods of using the crystals, and pharmaceutical compositions containing the crystals are described.

UY26454A 1999-11-30 2000-11-28 4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL UY26454A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
UY26454A1 true UY26454A1 (en) 2001-07-31

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26454A UY26454A1 (en) 1999-11-30 2000-11-28 4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL

Country Status (28)

Country Link
EP (1) EP1246804A1 (en)
JP (1) JP2003515592A (en)
KR (1) KR20020058057A (en)
CN (1) CN1402711A (en)
AP (1) AP2002002531A0 (en)
AU (1) AU1048801A (en)
BG (1) BG106854A (en)
BR (1) BR0015836A (en)
CA (1) CA2392979A1 (en)
CO (1) CO5271716A1 (en)
EA (1) EA200200510A1 (en)
EC (1) ECSP003792A (en)
EE (1) EE200200277A (en)
GT (1) GT200000199A (en)
HU (1) HUP0203521A2 (en)
IL (1) IL149097A0 (en)
IS (1) IS6338A (en)
MA (1) MA26845A1 (en)
MX (1) MXPA02005354A (en)
NO (1) NO20022558L (en)
OA (1) OA12099A (en)
PA (1) PA8506301A1 (en)
PE (1) PE20010904A1 (en)
PL (1) PL355892A1 (en)
TN (1) TNSN00231A1 (en)
TR (1) TR200201446T2 (en)
UY (1) UY26454A1 (en)
WO (1) WO2001040190A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CZ20033341A3 (en) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (en) * 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
MXPA04007438A (en) 2002-02-01 2004-10-11 Pfizer Prod Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials.
MXPA04007433A (en) * 2002-02-01 2004-10-11 Pfizer Prod Inc Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus.
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
IL161559A0 (en) 2002-08-30 2004-09-27 Japan Tobacco Inc Dibenzylamine derivatives and pharmaceutical compositions containing the same
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006508077A (en) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド PGD2 receptor antagonist for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2004056358A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
MXPA05010456A (en) * 2003-03-28 2006-03-21 Pfizer Prod Inc 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity.
CA2532931A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
EA200600737A1 (en) 2003-10-08 2006-10-27 Эли Лилли Энд Компани COMPOUNDS AND METHODS FOR THE TREATMENT OF DYSLIPIDEMIA
WO2005100298A1 (en) * 2004-04-13 2005-10-27 Merck & Co., Inc. Cetp inhibitors
MXPA06014716A (en) * 2004-06-24 2007-03-12 Lilly Co Eli Compounds and methods for treating dyslipidemia.
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
UA90706C2 (en) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CL2008000684A1 (en) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION THAT INCLUDES METFORMIN R - (+) LIPOATE AND A HMG-COA REDUCTASE INHIBITOR; UNIT DOSE FORMULATION; AND USE IN THE TREATMENT OF A DIABETIC COMPLICATION.
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AR077208A1 (en) 2009-06-30 2011-08-10 Lilly Co Eli ACID DERIVATIVES TRANS-4 - [[(5S) -5 - [[[3,5-BIS (TRIFLUOROMETIL) PHENYLE] METHYL] (2-METHYL-2H-TETRAZOL-5-IL) AMINO) -2,3, 4,5-TETRAHIDRO-7,9-DIMETIL-1H-1-BENZAZEPIN-1-IL) METHYL) -CYCLHEXANCARBOXYL AND ITS CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT, ITS USE TO PREPARE A MEDICAM
EP3795695A1 (en) 2014-07-30 2021-03-24 F. Hoffmann-La Roche AG Genetic markers for predicting responsiveness to therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
NO20022558D0 (en) 2002-05-29
WO2001040190A1 (en) 2001-06-07
IS6338A (en) 2002-04-12
EA200200510A1 (en) 2002-10-31
CO5271716A1 (en) 2003-04-30
MA26845A1 (en) 2004-12-20
CA2392979A1 (en) 2001-06-07
PA8506301A1 (en) 2002-08-26
PL355892A1 (en) 2004-05-31
ECSP003792A (en) 2002-04-23
OA12099A (en) 2006-05-04
TR200201446T2 (en) 2002-11-21
PE20010904A1 (en) 2001-09-10
CN1402711A (en) 2003-03-12
EP1246804A1 (en) 2002-10-09
AU1048801A (en) 2001-06-12
TNSN00231A1 (en) 2002-05-30
BR0015836A (en) 2002-08-06
AP2002002531A0 (en) 2002-06-30
MXPA02005354A (en) 2002-12-11
JP2003515592A (en) 2003-05-07
EE200200277A (en) 2003-10-15
HUP0203521A2 (en) 2003-02-28
NO20022558L (en) 2002-05-29
BG106854A (en) 2002-12-29
GT200000199A (en) 2002-05-23
KR20020058057A (en) 2002-07-12
IL149097A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
UY26454A1 (en) 4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL
ES2090713T3 (en) ORGANIC SALTS OF N, N'-DIACETIL-CYSTINE.
UY24555A1 (en) NEW COMPOUNDS
AR011069A1 (en) AMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL FORMULATIONS THAT UNDERSTAND THEM, AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AS AN INHIBITOR OF NITRIC OXIDE, INDUCIBLE SYNTHESES.
ES2053451T3 (en) A PROCEDURE FOR THE PREPARATION OF A COMPOUND THAT HAS USEFUL PHARMACOLOGICAL PROPERTIES.
GT199900102A (en) PHENOXIPROPANOLAMINES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
DK1007520T3 (en) 2-aminopyridines containing linked ring substituents as NOS inhibitors
ES2133543T3 (en) PIRROLIDINE AND OXAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE THROMBOCYTE AGGREGATION.
AR021355A1 (en) DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE
ES2134801T3 (en) CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE.
ES2178055T3 (en) SUBSTITUTED AMINIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
NO934628L (en) Retroviral protease inhibitors
PA8586801A1 (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
ECSP034531A (en) SUBSTITUTED DERIVATIVES OF C-CICLOHEXILMETILAMINA
DK0391171T3 (en) Use of di-styryl-phenyl-triglycol ether as crystallization inhibitor
AR046131A1 (en) CRYSTAL FORMS OF {2- [1- (3,5- BISTRIFLUORUROMETILBENCIL) -5- PIRIDIN-4-IL-1H- [1,2,3] TRIAZOL- 4-IL] PIRIDIN- 3-IL} - (2- CHLOROPHENYL) METANONE
DK1051177T3 (en) Steroidal 3-O-Sulfamate derivatives as inhibitors of oestrone sulfatase
ES2186989T3 (en) MALTITOL CRYSTALS OF SPECIFIC FORMS, CRYSTAL COMPOUNDS THAT CONTAIN THEM AND PROCEDURES FOR THEIR PREPARATION.
BR9814495A (en) Compound, process to prepare it, use of it, pharmaceutical composition, and, process
PA8495001A1 (en) NEW CRYSTAL FORMS OF AN ANTIBIOTIC MACROLIDO.
AR002978A1 (en) Benzamide compounds, pharmaceutical compositions containing them, methods of preparing the same and the use thereof.
MX9400165A (en) DERIVATIVES OF TER-BUTYLERGOLINE, PROCESS FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
MX9200874A (en) COMPOUNDS OF A SPECIFIC COMPOSITION, A PROCEDURE FOR ITS PRODUCTION AND USE.
ES2175661T3 (en) DERIVATIVES OF ISOFLAVONA, PROCEDURES FOR THE PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
HN2001000021A (en) NEW DERIVATIVES OF AMETAS HETEROCICLICAS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120529